Brean Capital set a $14.00 price objective on Trevena Inc. (NASDAQ:TRVN) in a research note released on Thursday morning. The brokerage currently has a a buy rating on the biopharmaceutical company’s stock.

TRVN has been the topic of a number of other research reports. Cowen and Company reissued a buy rating and issued a $13.00 target price on shares of Trevena in a report on Friday, August 5th. FBR & Co reissued a buy rating and issued a $13.00 target price on shares of Trevena in a report on Thursday, August 4th. TheStreet cut shares of Trevena from a hold rating to a sell rating in a report on Friday, June 17th. Zacks Investment Research raised shares of Trevena from a sell rating to a hold rating in a report on Wednesday, July 20th. Finally, Jefferies Group reissued a buy rating on shares of Trevena in a report on Friday, August 5th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have assigned a buy rating to the company’s stock. The stock currently has an average rating of Buy and a consensus target price of $14.30.

Shares of Trevena (NASDAQ:TRVN) opened at 7.01 on Thursday. The stock’s market cap is $365.77 million. Trevena has a 52 week low of $5.58 and a 52 week high of $13.10. The stock’s 50 day moving average price is $6.96 and its 200 day moving average price is $7.28.

Trevena (NASDAQ:TRVN) last issued its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.36) by $0.01. Trevena had a negative return on equity of 45.01% and a negative net margin of 841.00%. Equities research analysts anticipate that Trevena will post ($1.55) EPS for the current fiscal year.

A number of hedge funds have recently modified their holdings of the company. GSA Capital Partners LLP purchased a new position in Trevena during the second quarter worth approximately $344,000. Bourgeon Capital Management LLC raised its position in Trevena by 70.8% in the second quarter. Bourgeon Capital Management LLC now owns 54,300 shares of the biopharmaceutical company’s stock worth $342,000 after buying an additional 22,500 shares in the last quarter. Northpointe Capital LLC raised its position in Trevena by 92.6% in the second quarter. Northpointe Capital LLC now owns 379,186 shares of the biopharmaceutical company’s stock worth $2,389,000 after buying an additional 182,261 shares in the last quarter. Alps Advisors Inc. raised its position in Trevena by 28.3% in the second quarter. Alps Advisors Inc. now owns 73,294 shares of the biopharmaceutical company’s stock worth $462,000 after buying an additional 16,169 shares in the last quarter. Finally, First Manhattan Co. purchased a new position in Trevena during the second quarter worth approximately $729,000. Hedge funds and other institutional investors own 75.43% of the company’s stock.

About Trevena

Trevena Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and intends to commercialize therapeutics that use an approach to target G protein coupled receptors (GPCRs). Using its product platform, the Company has identified and advanced three differentiated product candidates: Oliceridine (TRV130), TRV027 and TRV250.

5 Day Chart for NASDAQ:TRVN

Receive News & Ratings for Trevena Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.